Full Text
Secukinumab Vs. Adalimumab for Treatment of Ankylosing Spondylitis- A Cost Per Responder Analysis at 52 Weeks from an Argentinian Perspective

Abstract

Authors

M Barbeau PM Bianculli E Nikoglou P Gunda SM Jugl A MacPherson

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×